The (apparent) antibody paradox in COVID-19

Area of Science:

• Immunology
• Virology
• Infectious Diseases

Background:

• The immunological response to COVID-19, caused by SARS-CoV-2, is not fully understood.
• Severe COVID-19 is associated with an inappropriate host inflammatory reaction.
• The precise role of antibodies in COVID-19 pathogenesis and protection remains unclear.

Purpose of the Study:

• To review the current understanding of the immunological response to SARS-CoV-2.
• To evaluate the roles of humoral and cellular immunity in COVID-19.
• To discuss the implications of the SARS-CoV-2 Omicron variant on immunity.

Main Methods:

• Review of existing literature on COVID-19 immunology.
• Analysis of clinical data regarding antibody titers, viral loads, and T cell responses.
• Discussion of findings in the context of SARS-CoV-2 variants.

Main Results:

• Antibodies to SARS-CoV-2 have shown evidence of both protection and harm, with high titers not preventing severe disease.
• Therapeutic convalescent plasma infusions have not demonstrated clear benefit in COVID-19 treatment.
• A vigorous T-cell response appears to be protective, while delayed or low-avidity T cell responses are linked to severe COVID-19.

Conclusions:

• T cell responses to SARS-CoV-2 are likely the dominant long-term protective mechanism after infection or vaccination.
• The quality and magnitude of antibody responses may reflect underlying T cell immunity.
• Understanding of COVID-19 immunity requires revision due to the emergence of variants like Omicron.